These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22942712)

  • 1. Effect of PACAP in central and peripheral nerve injuries.
    Tamas A; Reglodi D; Farkas O; Kovesdi E; Pal J; Povlishock JT; Schwarcz A; Czeiter E; Szanto Z; Doczi T; Buki A; Bukovics P
    Int J Mol Sci; 2012; 13(7):8430-8448. PubMed ID: 22942712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo.
    Reglodi D; Kiss P; Lubics A; Tamas A
    Curr Pharm Des; 2011; 17(10):962-72. PubMed ID: 21524257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of PACAP in ischemia.
    Reglodi D; Vaczy A; Rubio-Beltran E; MaassenVanDenBrink A
    J Headache Pain; 2018 Mar; 19(1):19. PubMed ID: 29500688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative Routes of Administration of the Neuroprotective Pituitary Adenylate Cyclase Activating Polypeptide.
    Reglodi D; Atlasz T; Jungling A; Szabo E; Kovari P; Manavalan S; Tamas A
    Curr Pharm Des; 2018; 24(33):3892-3904. PubMed ID: 30417775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects.
    Atlasz T; Szabadfi K; Kiss P; Racz B; Gallyas F; Tamas A; Gaal V; Marton Z; Gabriel R; Reglodi D
    Ann N Y Acad Sci; 2010 Jul; 1200():128-39. PubMed ID: 20633141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of PACAP for neurodegenerative diseases.
    Yang R; Jiang X; Ji R; Meng L; Liu F; Chen X; Xin Y
    Cell Mol Biol Lett; 2015 Jun; 20(2):265-78. PubMed ID: 26204407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents.
    Reglodi D; Tamas A; Jungling A; Vaczy A; Rivnyak A; Fulop BD; Szabo E; Lubics A; Atlasz T
    Neurotoxicology; 2018 May; 66():185-194. PubMed ID: 29604313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases.
    Lee EH; Seo SR
    BMB Rep; 2014 Jul; 47(7):369-75. PubMed ID: 24856828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.
    Bourgault S; Chatenet D; Wurtz O; Doan ND; Leprince J; Vaudry H; Fournier A; Vaudry D
    Curr Pharm Des; 2011; 17(10):1002-24. PubMed ID: 21524253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
    Somogyvári-Vigh A; Reglodi D
    Curr Pharm Des; 2004; 10(23):2861-89. PubMed ID: 15379674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pituitary adenylate cyclase-activating polypeptide on facial nerve recovery in the Guinea pig.
    Kimura H; Kawatani M; Ito E; Ishikawa K
    Laryngoscope; 2003 Jun; 113(6):1000-6. PubMed ID: 12782812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research advance of the protective role of PACAP in the nervous system diseases].
    Mao SS; Zhang YM
    Sheng Li Ke Xue Jin Zhan; 2011 Aug; 42(4):276-80. PubMed ID: 22066419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on spinal cord injury.
    Tsuchikawa D; Nakamachi T; Tsuchida M; Wada Y; Hori M; Farkas J; Yoshikawa A; Kagami N; Imai N; Shintani N; Hashimoto H; Atsumi T; Shioda S
    J Mol Neurosci; 2012 Nov; 48(3):508-17. PubMed ID: 22674051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury.
    Jaworski DM
    Cell Tissue Res; 2000 May; 300(2):219-30. PubMed ID: 10867818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic and retinoprotective functions of PACAP.
    Shioda S; Takenoya F; Wada N; Hirabayashi T; Seki T; Nakamachi T
    Anat Sci Int; 2016 Sep; 91(4):313-24. PubMed ID: 27324639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Pacap on Schwann Cells: Focus on Nerve Injury.
    Maugeri G; D'Amico AG; Musumeci G; Reglodi D; D'Agata V
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PACAP stimulates functional recovery after spinal cord injury through axonal regeneration.
    Tsuchida M; Nakamachi T; Sugiyama K; Tsuchikawa D; Watanabe J; Hori M; Yoshikawa A; Imai N; Kagami N; Matkovits A; Atsumi T; Shioda S
    J Mol Neurosci; 2014 Nov; 54(3):380-7. PubMed ID: 25074795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PACAP as a neuroprotective factor in ischemic neuronal injuries.
    Shioda S; Nakamachi T
    Peptides; 2015 Oct; 72():202-7. PubMed ID: 26275482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration.
    Atlasz T; Szabadfi K; Kiss P; Tamas A; Toth G; Reglodi D; Gabriel R
    Brain Res Bull; 2010 Mar; 81(4-5):497-504. PubMed ID: 19751807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary adenylate cyclase activating polypeptide (PACAP) signalling exerts chondrogenesis promoting and protecting effects: implication of calcineurin as a downstream target.
    Juhász T; Matta C; Katona É; Somogyi C; Takács R; Gergely P; Csernoch L; Panyi G; Tóth G; Reglődi D; Tamás A; Zákány R
    PLoS One; 2014; 9(3):e91541. PubMed ID: 24643018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.